BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32219446)

  • 1. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
    Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
    Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
    Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
    Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
    Cuiffo B; Ren R
    Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
    Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
    Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
    Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.
    Song SP; Hennig A; Schubert K; Markwart R; Schmidt P; Prior IA; Böhmer FD; Rubio I
    Biochem J; 2013 Sep; 454(2):323-32. PubMed ID: 23758196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
    Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
    Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
    Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
    J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
    Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE
    Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies.
    Yu F; Qian Z
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation.
    Jin X; Ng V; Zhao M; Liu L; Higashimoto T; Lee ZH; Chung J; Chen V; Ney G; Kandarpa M; Talpaz M; Li Q
    Dis Model Mech; 2022 May; 15(5):. PubMed ID: 35352806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.
    Wandler A; Shannon K
    Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28778967
    [No Abstract]   [Full Text] [Related]  

  • 19. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
    Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
    Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.